Neurenati Therapeutics Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 5

Employees

  • Latest Deal Type
  • Seed

  • Latest Deal Amount
  • $2.17M

  • Investors
  • 3

Neurenati Therapeutics General Information

Description

Developer of novel regenerative therapies intended for the treatment of Hirschsprung disease. The company focuses on developing innovative therapy via growth factor to treat newborns with Hirschsprung disease, a life-threatening gastrointestinal birth defect, providing doctors with a non-surgical alternative to treat rare GI diseases in newborns.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 630 René-Lévesque Boulevard West
  • 20th Floor
  • Montreal, Quebec H3B 1S6
  • Canada
+1 (514)
Primary Industry
Biotechnology
Other Industries
Drug Delivery
Vertical(s)
Corporate Office
  • 630 René-Lévesque Boulevard West
  • 20th Floor
  • Montreal, Quebec H3B 1S6
  • Canada
+1 (514)

Neurenati Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Neurenati Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Seed Round 25-Sep-2025 $2.17M Completed Pre-Clinical Trials
2. Seed Round 18-Apr-2024 Completed Pre-Clinical Trials
1. Seed Round 29-Feb-2024 $889K $889K Completed Pre-Clinical Trials
To view Neurenati Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Neurenati Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel regenerative therapies intended for the treatment of Hirschsprung disease. The company focuses on dev
Biotechnology
Montreal, Canada
5 As of 2025

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Neurenati Therapeutics Competitors (1)

One of Neurenati Therapeutics’s competitors is Harvard University, a Corporation company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Harvard University Corporation Cambridge, MA
You’re viewing 1 of 1 competitors. Get the full list »

Neurenati Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Neurenati Therapeutics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Angel (individual) Minority
Investissement Quebec PE/Buyout Minority
Genson Capital Venture Capital Minority
To view Neurenati Therapeutics’s complete investors history, request access »

Neurenati Therapeutics FAQs

  • When was Neurenati Therapeutics founded?

    Neurenati Therapeutics was founded in 2020.

  • Where is Neurenati Therapeutics headquartered?

    Neurenati Therapeutics is headquartered in Montreal, Canada.

  • What is the size of Neurenati Therapeutics?

    Neurenati Therapeutics has 5 total employees.

  • What industry is Neurenati Therapeutics in?

    Neurenati Therapeutics’s primary industry is Biotechnology.

  • Is Neurenati Therapeutics a private or public company?

    Neurenati Therapeutics is a Private company.

  • What is the current valuation of Neurenati Therapeutics?

    The current valuation of Neurenati Therapeutics is .

  • What is Neurenati Therapeutics’s current revenue?

    The current revenue for Neurenati Therapeutics is .

  • How much funding has Neurenati Therapeutics raised over time?

    Neurenati Therapeutics has raised $4.31M.

  • Who are Neurenati Therapeutics’s investors?

    , Investissement Quebec, and Genson Capital have invested in Neurenati Therapeutics.

  • Who are Neurenati Therapeutics’s competitors?

    Harvard University is a competitor of Neurenati Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process